




Figure S1. Ipilimumab markedly down-regulates the level of cell surface CTLA-4, Related to Figure 1

(a) Mouse splenocytes were isolated and stained with surface markers (CD45, CD4 and CD8). Cells were fixed and incubated with 10 μ g/ml of hlgG (hlgG block) or Ipilimumab (Ipi block) at 4°C for half an hour. After several washing, cells were staining with anti-

CTLA-4 (BNI3) and anti-Foxp3. The CTLA-4 expression in Foxp3⁺ Tregs were shown. A color-matched Isotype control staining was performed for BNI3 staining (shown as Iso).

(b) HEK293T cells transfected with OFP-tagged human CTLA-4 were treated with either control hlgG or Ipilimumab for 4 hrs at 37°C. The fluorescence of OFP was detected by flow cytometry and the geometric mean of the fluorescence were shown. (c) Plasma membrane proteins in CTLA-4 transfected HEK293T cells were isolated. CTLA-4, Na⁺-K⁺ ATPase and Tubulin were detected by western blot. (d&e) CTLA-4^{h/h}-KI neonatal mice were i.p. treated with 100 µg of control hlgG Fc or mouse anti-PD-1 antibody. After 24 hrs, cell surface (d) and total CTLA-4 (e) in Tregs isolated from mice lung and spleen were evaluated by flow cytometry. (f&g) naïve or MC38 bearing-*Ctla4*^{h/h} mice (n=5-7) were i.p. treated with control hlgG Fc or Ipilimumab (100 µg/mouse) on day 17 after tumor inoculation (tumors had an average size of 8-10 mm in diameter). Spleen Treg from the *Ctla4*^{h/h} adult mice were analyzed for cell surface (f) and total (g) CTLA-4 expression by flow cytometry. Data in d-g are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Representative data of two independent experiments in (a) were shown. Representative data of three independent experiments in (b) and (c) were shown. Representative data of three independent experiments in (d-g) were shown.